AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01109459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric vision screening
Description: Website presenting case-based education about amblyopia and strabismus with tailoring based on knowledge and interactive with responses collected on line. Has a tool box for office materials to promote and encourage guideline based performance.
Study NCT02134574 — intervention group
Intervention type: BIOLOGICAL
Intervention: hematologic malignancy
Description: hematologic malignancy with a sampling of blood
Study NCT01892423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetaphil Moisturizing Lotion Daily Advance
Study NCT02277821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stendo pulsating suit System
Description: The Stendo system, a multilayer pulsatile inflatable suit is applied to the lower limbs and the abdomen. This device induces a sequential compartmentalized compression synchronized with each diastolic phase of the cardiac cycle, each phase evolving centripetally (lower limbs to abdomen).
Study NCT02987595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-grain rye, high lignan
Description: Intervention week 1-8: 50 g rolled rye + 50 g puffs + 4 pieces of crisp bread + 70 g pasta. Additionally for intervention week 4-8: 4 lignan capsules per day
Study NCT02987595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-grain wheat, low lignan
Description: Intervention week 1-8: 100 g puffs + 4 pieces of crisp bread + 70 g pasta.
Study NCT03555721 — intervention group
Intervention type: OTHER
Intervention: Oral examination with incandescent light
Description: Suspicious oral lesions will be identified by oral examination with incandescent light.
Study NCT03555721 — intervention group
Intervention type: OTHER
Intervention: Oral examination with OralID
Description: OralID uses a proven, optically based fluorescence technology that provides the clinician an aid in visualization of oral cancer, pre-cancer and other abnormal lesions.
Study NCT03555721 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy
Description: Tissue will be collected to identify pre-cancerous or cancerous cells
Study NCT03555721 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CytID
Description: CytID™ is an adjunctive process that is a noninvasive, pain-free, chair-side procedure for assessment of suspicious oral cavity lesions using a brush swab. The test is based on an objective measure of gross changes in the nuclear DNA content of oral epithelial cells; thereby, providing information about the pre-cancerous or cancerous state of a lesion.
Study NCT03555721 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: hpvID
Description: hpvID™ testing can detect all major HPV types and shows the current HPV status of the patient. This provides additional clinical information to correlate and compare hpvID™ trends with routine standard of care biopsy or cytology results.
Study NCT02638662 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Questionnaires are completed such as self-evaluation questionnaire (STAI), Beck Depression Inventory, FertiQol International and Daily stress questionnaire
Study NCT04303494 — intervention group
Intervention type: BIOLOGICAL
Intervention: immunisation
Description: combined diphtheria, tetanus, acellular pertussis, poliomyelitis, hepatitis B, ± Haemophilus influenzae type B and simultaneous pneumococcus (PCV13) vaccination
Study NCT03914144 — intervention group
Intervention type: OTHER
Intervention: Catheter insertion
Description: A data collection sheet will be assigned for every patient who is recruited for the study. The clinician caring for the patient will be asked to fill in this form after the delivery has occurred. The form essentially will describe if the patient received any catheter during the delivery and if so, an indwelling catheter or an intermittent (in/out) catheter and how many episodes this occurred.
Study NCT03197961 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: tenofovir/emtricitabine
Description: At the enrollment visit, participants will be given a 14-day supply of tenofovir/emtricitabine 200mg/300mg to take once daily for 14 days. Drug concentrations will be measured as outlined in the outcomes section at the end of the two week period. The tenofovir/emtricitabine 200mg/300mg course will be repeated approximately 2 to 6 weeks later to allow washout of tenofovir/emtricitabine.
Study NCT03197961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMPA
Description: After completion of the first 14 day course of tenofovir/emtricitabine depot medroxyprogesterone acetate 150 mg will be administered as intramuscular injection.
Study NCT03251183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive Cardiovascular magnetic resonance (CMR)
Description: Cardiovascular magnetic resonance (CMR) provides non-invasive, radiation-free and in-depth evaluation of myocardial structure and function. In addition to established tools for assessment of cardiac volume, mass, function and regional myocardial scar with late Gadolinium enhancement (LGE), several novel quantitative CMR parameters will be assessed including T1-mapping or fully quantitative perfusion Imaging.
Study NCT05884060 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No interventions
Study NCT01240174 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Demonstration of near zero antibiotic prescribing for patients with acute bronchitis
Description: A controlled, continuously-monitored, implementation of an EHR-integrated diagnosis and treatment algorithm for acute bronchitis in a large, diverse primary care practice.
Study NCT00675740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: tablets 4 mg daily
Study NCT00675740 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical exercise
Description: stationary bike 5-6 times a week
Study NCT00675740 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: control
Description: control without intervention
Study NCT03251183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Blood samples will eventually be analysed for markers related to heart failure (BNP/NT)-pro-BNP, myocardial inflammation and fibrosis (cytokine profiling, Galectin-3, Procollagen Type I and III, hsCRP). Whole blood will be frozen for DNA isolation and genome analysis. Peripheral blood mononuclear cells will be isolated by Ficoll in a subset of patients and will be used for RNA isolation allowing RNA-seq or reverse transcription (RT) - polymerase chain reaction (PCR) analysis.
Study NCT03251183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TTE (EchoErgo)
Description: Measurements will include cavity dimensions, flow velocities, myocardial motion velocity and strain as well as for change of parameters during ergometric stress.
Study NCT03251183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Invasive pressure-volume (PV) Loops
Description: Multiple parameters (including EDPVR, ESPVR, dp/dt min, Tau, Ea) will be derived from the various PV loop assessments and additional relevant parameters will be calculated. Right ventricular and pulmonary pressures including pulmonary vascular resistance will be measured with Swan-Ganz catheters using right venous femoral approach.
Study NCT04213885 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PXL 330 Platinum device/Riboflavin
Description: 30mW, 5 sec, 5 sec off, 10 minutes of illumination
Study NCT03251183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Left ventricular (LV) biopsy
Description: A set of myocardial biopsies for each patient will be stained with Masson Trichrome for qualitative and quantitative assessment of the collagen volume fraction; fat droplets will be identified by red oil staining, Congo Red for amyloid immunohistology will be used to determine total leukocytes (CD45), T-cells (CD3) and monocytes/macrophages (CD68).~A second set of biopsies will be frozen immediately and stored at -80°. Western blot analysis will be performed to determine alterations at the myofilament level including titin isoform composition and phosphorylation status.
Study NCT02754323 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Apparatus CODESNA
Description: The inclusion period is evaluated at one month and the participation of each patient is two days. One day or the subject performs the evaluation of chronic stress by CODESNA and following through questionnaires and another day to 3 weeks / one month apart, to perform a second chronic stress measurement with tool CODESNA to evaluate its reproducibility and reliability.
Study NCT04525742 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Difficulties lived by disabled children's parents in the period of COVID-19 pandemic
Description: It will be a cross sectional study to obtain the information on difficulties lived by disabled children's parents during recent pandemic period
Study NCT03205514 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NSTE-ACS with intermediate stenosis and negative FFR
Description: Patients will undergo intracoronary imaging evaluation with IVUS-NIRS and OCT, endothelial function and inflammatory state evaluation.
Study NCT01625429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel 125mg/m2, day 1, 8, 15, q4w; carboplatin AUC 2, day 1, 8, 15, q4w; for HER-2 positive patients: trastuzumab loading dose 4mg/kg, then 2mg/kg, day 1, 8, 15, 22, q4w. All patients will receive up to four cycles except for unacceptable toxicity
Study NCT00989651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00989651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT03467594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: • Exercises will be conducted in an interval training format (60 second exercise bursts, followed by 75 seconds rest). The exercise bursts are designed to elicit ≥85% of participants age predicted maximum heart rate and will be tailored to each individuals fitness level and ability. Exercise sessions will be conducted 3 times per week for 8 weeks and will last between 15-25 minutes.
Study NCT03115879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip mobilization
Description: High velocity low amplitude hip mobilization of the experimental group
Study NCT03115879 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hip manipulation simulation
Description: Hip manipulation simulation
Study NCT01580462 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: Study plan - data collecting:~Patients will attend diabetes clinic as usual, with one additional visit in the middle of the 3-months period. During those visits - V0, V1 and V2, data from glucometers and insulin pumps will be downloaded.
Study NCT01709643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High fat breakfast
Description: The HF breakfast will consist of sausage rolls (saucijzenbroodjes), available at the local Albert Heijn (Albert Heijn B.V., Zaandam, The Netherlands).
Study NCT00989651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IP
Study NCT01809314 — intervention group
Intervention type: DRUG
Intervention: Epoetin beta
Description: Treatment will be given according to standard of care and the Summary of Product Characteristics during the study.
Study NCT04418427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 6E11 vg/eye of ADVM-022
Description: ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-deficient adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept
Study NCT00989651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00989651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV or IP
Study NCT00989651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT03600155 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03600155 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04418427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2E11 vg/eye of ADVM-022
Description: ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-deficient adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept
Study NCT01709643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: HF breakfast with protein
Description: For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls.
Study NCT02580110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Study NCT02580110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stevia glycosides
Study NCT02580110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saccharin
Study NCT02478294 — intervention group
Intervention type: PROCEDURE
Intervention: Thoracoscopic LAA Excision plus AF Ablation
Description: In this group, patients receive thoracoscopic LAA excision plus AF ablation, which means thoracoscopic left atrial appendage excision plus atrial fibrillation ablation.
Study NCT02478294 — intervention group
Intervention type: DRUG
Intervention: Warfarin or Novel Oral Anticoagulants
Description: In this group, patients receive warfarin or novel oral anticoagulants
Study NCT02721459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL888
Description: Level 1: XL888 30 mg by mouth (PO) twice weekly (BIW). Level 2: XL888 45 mg PO BIW.~Level 3: XL888 60 mg PO BIW. Level 4: XL888 90 mg PO BIW.
Study NCT02721459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib 720 mg by mouth twice a day (BID)
Study NCT02721459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib 40 mg by mouth once daily (QD). Administered 3 weeks on, 1 week off.
Study NCT03902223 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Enhanced Screening Protocol for Cardiac Sarcoidosis.
Description: To utilize enhanced screening tests for cardiac sarcoidosis in an undiagnosed and potentially under-diagnosed patient population to determine the rate of missed cardiac sarcoidosis diagnosis. Following testing by the standard screening tests, this intervention includes a subsequent echocardiogram and a wearable ECG, also known as a Holter Monitor or ambulatory ECG.
Study NCT03902223 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Routine Screening for Suspected Cardiac Sarcoidosis
Description: To utilize standard of care screening tests for cardiac sarcoidosis. This includes symptom check and a standard ECG.
Study NCT06535191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assistive Soft Skills and Employment Training (ASSET)
Description: ASSET program is a manualized, theory-driven, 10-week soft skills intervention for autistic individuals, who seek employment or who wish to maintain employment by improving work-related social skills. Throughout a 10-week curriculum offered in a school-based group setting, ASSET addresses the following competencies for workplace success: Communication, Networking, Enthusiasm and Attitude, Teamwork, Problem-Solving and Critical Thinking, Professionalism, Mental Health and Stress Management, and Awareness of Self and Others.
Study NCT04418427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Commercially available Active Comparator
Study NCT04233099 — intervention group
Intervention type: PROCEDURE
Intervention: Raman analysis of saliva with data collection and analysis
Description: Saliva collection and processing to all the enrolled subjects and consecutive Raman analysis of the biological fluid. Statistical processing of the collected data.
Study NCT01134029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care
Description: This group receives 2 years of a stepped care intervention including provider visits, health educator sessions, phone calls and mailings and availability of self management and group sessions, text messaging and a smoker's quit line.
Study NCT02073084 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: K-877 Low Dose
Description: K-877 Low Dose
Study NCT02073084 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin
Study NCT04384692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HSCT
Study NCT04384692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT04384692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04384692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT04384692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT04384692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT04384692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO
Study NCT04384692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO
Study NCT04384692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO
Study NCT04418427 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Commercially available Active Comparator
Study NCT02454972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lurbinectedin (PM01183)
Study NCT01637311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POEM
Description: Peroral endoscopic myotomy (POEM) has recently been described as a new minimally invasive endoscopic myotomy technique intending a permanent cure from primary achalasia.
Study NCT03645083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone call
Description: Participants in the intervention group receive a one-time telephone call reminder to attend follow-up treatment at the acupuncture clinic
Study NCT03645083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message
Description: Participants in the intervention group receive a one-time text messaging reminder to attend follow-up treatment at the acupuncture clinic
Study NCT01956279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone
Description: Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x 28 days
Study NCT01956279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 50mg BID x 14 days, followed by Placebo 150 x 14 days, followed by Placebo 250 mg BID x 28 days
Study NCT01584778 — intervention group
Intervention type: OTHER
Intervention: eosinophil cationic protein
Description: Serum eosinophil cationic protein levels
Study NCT01795703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone will be administered orally as 1000 milligram (mg) per day for 28-daily dosing cycles which will be continued until disease progression or unacceptable toxicity.
Study NCT01795703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
Study NCT02073084 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Study NCT02073084 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: K-877 High Dose
Description: K-877 High Dose
Study NCT03750201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct Selective Trabeculoplasty
Description: Laser surgery by automated direct automated SLT device to lower intraocular pressure
Study NCT03750201 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Trabeculoplasty
Description: Laser surgery by standard SLT device to lower intraocular pressure
Study NCT01212367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 721015
Description: 1.0 x 10e12 viral particles on Days 1 and 4
Study NCT01212367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 721015
Description: 3.0 x 10e11 viral particles on Days 1 and 4
Study NCT03289910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT03289910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT03289910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Given IV
Study NCT03289910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Given IV
Study NCT03289910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV
Study NCT03289910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan Hydrochloride
Description: Given IV
Study NCT03289910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO